Protalix BioTherapeutics and Chiesi Global Rare Diseases announced that PRX-102 has received marketing authorization in the EU for the treatment of Fabry disease.
AI Assistant
PROTALIX BIOTHERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.